PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449/PTO				Complete if Known	`	
				Application Number	09/688,017		
-	RMATION		•	Filing Date	October 13, 2000	 	
STA	TEMENT BY	YA	PPLICANT	First Named Inventor Lu, Peter S., et. al.			
				Art Unit	1644		
	(use as many she	ets as	necessary)	Examiner Name	DeCloux, Amy M.		
Page	1	of	5	Attorney Docket Number	020054-001110US		

		Document Number		ļ ;	
Examiner	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
MB	A1	US-5,632,994	05/27/97	Reed et al.	RECEIVE
	A2	US-5,747,245	05/05/98	Reed et al.	
	А3	US-5,876,939	03/02/99	Reed et al.	- FFR 0 ≥ 2304
	A4	U.S. Application No. 07/724,553		Lu et al.	
HB	A5	U.S. Application No. 09/722,069		Lu et al.	TECH CENTER 1003/2

				FOR	EIGN PA	TENT DOCUME	ENTS	· •	
Examiner	Cite	Foreign Patent Document		<u> </u>	Name of Batastas	Pages, Columns, Lines,	Т		
Initials* No	No.1	Country Code ³		Number ⁴ Kind Co	de ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	1
MB	B1	PCT	₹	WO 98/05347	A1	02-12-1998			
1	B2	PCT	i	WO 98/23781	A1	06-04-1998			
	B3	PCT	1	WO 98/40407	A1	09-17-1998			
	B4	PCT	1	WO 99/03974	A1	01-28-1999			1
	B5	PCT	1	WO 99/07846	A1	02-18-1999			
	B6	PCT	i	WO 00/15794	A1	03-23-2000			
	B7	PCT	1	WO 00/31124	A2	06-02-2000			
	B8	PCT	*	WO 00/48002	A1	08-17-2000			
	B9	PCT	1	WO 00/69896	A2	11-23-2000	Arbor Vita Corp		17
	B10	PCT		WO 00/69897	A2	11-23-2000	Arbor Vita Corp		
	B11	PCT	,	WO 00/69898	A2	11-23-2000	Arbor Vita Corp		Ē
MA	B12	PCT	1	WO 02/42422	A2	05-30-2002	Arbor Vita Corp		

	· /n		. ,	
Examiner Signature	10	Date Considered	3/22/	04
TENANTHE TO THE TOTAL TO THE TENANTHE TOTAL TO THE TENANTHE TO THE TENANTHE TOTAL TOTAL TO THE TENANTHE TOTAL TOTAL TO THE TENANTHE TOTAL				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant's unique citation designation number (optional). Find Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (04-03)

Complete if Known

October 13, 2000

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Application Number

Filing Date

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

First Named Inventor Art Unit **Examiner Name**

Lu, Peter S., et. al. 1644 DeCloux, Amy M.

09/688,017

(use as many sheets as necessary)

of 5 Attorney Docket Number 020054-001110US Page

		NON PATENT LITERATURE DOCUMENTS].
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2	
MB	C1	Altin, J. and Sloan, E. "The role of CD45 and CD45-associated molecules in T cell activation" Immunology and Cell Biology, 1997, pp. 430-445, Vol. 75.		
1	C2	Bals, R. et al. "Augmentation of Innate Host Defense by Expression of a Cathelicidin Antimicrobial Peptide", Infection and Immunity, November 1999, pp. 6084-6089, Vol. 67, No. 11.		
7	сз √	Barclay, A., et al., "The Leukocyte Antigen Factsbook", Harcourt Braces & Company, page 363, (1997).		
	C4	Bruyns, E. et al. "Identification of the Sites of Interaction between Lyphocyte Phosphatase-associated Phophoprotein (LPAP) and CD45", <i>Journal of Biological Chemistry</i> , December 29, 1996, pp. 31376, Vol. 270, No. 52, U.S.A.	CF	9\ <i>J</i>
	C5	Cherukuri, A. et al. "Floating the raft hypothesis: lipid rafts play a role in immune cell activation", Immunity, June 2001, pp.657-660, Vol. 14, Cell Press. Ping J. Et al. "Biochemical and Eurotional Analysis of Mice Deficient in Environment the CD45"		,
	C6 ¹	Associated Phosphoprotein LPAP", European Journal of Immunology, 29(12):3956-61 (1999)		
	C7	Doyle, D. A., et al., "Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ", Cell, 85(7):1067-76, (1996).	TER	160
	C8	Faulkner, G. et al. "A New Z-band Alternatively Spliced PDZ-motif Protein." The Journal of Cell Biology, July 26, 1999; pp. 465-475, Vol. 146, No. 2.		
	C9	Gardiol, D. et al. "Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation", Oncogene, 18(40):5487-5496, (1999).		
	C10	Gee., S.H., et al., "Cyclic Peptides as Non-carboxyl-terminal Ligands of Syntrophin PDZ Domains", The Journal of Biological Chemistry, 273(34):21980-21987, (1998).		
2	C11	Hanada, T., et al., "Human Homologue of the Drosophila Discs Larger Tumor Suppressor Binds to p56 ^{lck} Tyrosine Kinase and Shaker Type Kv1.3 Potassium Channel in T. Lymphocytes", <i>The Journal of Biological Chemistry</i> , 272(43):26899-26904, (1997).		
	C12	Kiyono, T. et al. "Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the <i>Drosophila</i> discs large tumor suppressor protein", <i>Proc. Natl. Acad. Sci.</i> , October 1997, pp. 11612-11616, Vol. 94, U.S.A.		
MB	C13	Kobayashi, I., et al., "Identification of an Autoimmune Enteropathy-related 75-kilodalton Antigen", Gastroenterology, October 1999, pp. 823-830, Vol. 117, No. 4.		

Examiner Signature	10	Date Considered	3/22/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 5

Substitute for form 1449/PTO

Complete if Known **Application Number** 09/688,017 Filing Date October 13, 2000 First Named Inventor Lu, Peter S., et. al. Art Unit 1644 **Examiner Name** DeCloux, Amy M. Attorney Docket Number 020054-001110US

		NON PATENT LITERATURE DOCUMENTS]
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
MB	C14	Maekawa, K., et al., "Association of Protein-Tyrosine Phosphatasee PTP-BAS with the Transcription-factor-inhibitory Protein IκΒα Through Interaction Between the PDZ1 Domain and Ankyrin Repeats", Biochemical Journal, 337(2):179-187, (1999).		
	C15	McKusick, Victor A.; OMIM Database entry entitled, '147138 Fc Fragment of IgE, High Affinity I, Receptor for, Beta Subunit; FCER1B', www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim?147138, 08/27/1992.		
	C16	Nagase, T. et al. "Prediction of the Coding Sequence of Unidentified Human Genes. V1. The Coding Sequences of 80 New Genes (KIAA0201-KIAA0280) Deduced by Analysis of cDNA Clones from Cell Line KG-1 and Brain", DNA Research, 1996, pp. 321-329, Vol. 3.		
	C17	Nagase, 1. et al. "Prediction of the Coding Sequence of Unidentified Human Genes. V1. The Coding Sequences of 80 New Genes (KIAA0201-KIAA0280) Deduced by Analysis of cDNA Clones from Cell		0 5 2504 TER 1000/ 29
	C18	Nishihara, H. et al. "Non-adherent cell-specific expression of DOCK2, a member of the human CDM-family proteins", <i>Biochimica et Biophysica Acta</i> , 1999, pp. 179-187, Elsevier Publishing.		
	C19	Nishihara, H. "Analysis of Hematopoietic Cell Specific Protein, M-DOCK", Hokkaido Igaku Zasshi, March 1999, p. 157-166, Vol. 74, No. 2.		
	C20	Patel, V. et al., "A Molecular Framework for 2-Step T Cell Signaling: Lck Src Homology 3 Mutations Discriminate Distinctly Regulated Lipid Raft Reorganization Events", <i>Journal of Immunology</i> , 166(2):754-64 (2001).		
	C21	Rasooly, Rebekah S.; OMIM Database entry entitled, "603122 Dedicator of Cytokinesis 2; Dock 2" www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim?603122, 10/12/1998.		
	C22	Reynaud, C. et al., "The PDZ Protein TIP-1 Interacts with the Rho Effector Rhotekin and Is Involved in Rho Signaling to the Serum Response Element", <i>The Journal of Biological Chemistry</i> , 275(43):33962-33968, (2000).		
	C23	Rousset, R., et al., "The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins" <i>Oncogene</i> , 16(5):643-54, (1998).		
MB	C24	Saras, J., et al., "PDZ Domains Bind Carboxy-Terminal Sequences of Target Proteins", Tibs Trends in Biochemical Sciences, en, Elsevier Publication, Cambridge, 21(12):455-458, (1996).		

Examiner Signature	Date Considered	3/22/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

EXAMINER: Initial if reference of sidered, whether or not citation is in conformance with MPEP but. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

Page

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 5

	Complete if Known	,
Application Number	09/688,017	
Filing Date	October 13, 2000	
First Named Inventor	Lu, Peter S., et. al.	
Art Unit	1644	
Examiner Name	DeCloux, Amy M.	
Attorney Docket Number	020054-001110US	

_	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MB	C25	Schepens, J., et al., "The Neuronal Nitric Oxide Synthase PDZ Motif Binds to -G(D.E)XV Carboxy Terminal Sequences", Febs Letters, 409(1-2):53-56, (1997).	
	C26	Schraven, Burkhart et al. "LPAP, a Novel 32-kDa Phosphoprotein That Interacts With CD45 in Human Lymphocytes", <i>J. Biological Chemistry</i> , Nov. 18, 1994; pp. 29102-29111, Vol. 269, No. 46.	
	C27 '	Shibuya, A., et al., "DNAM-1, A Novel Adhesion Molecule Invovled in the Cytolytic Function of T Lymphocytes", <i>Immunity</i> , 4:573-581, (1996).	
	.j C28	Shibuya, A., et al., "Protein Kinase C is Involved in the Regulation of Both Signaling and Adhesion Mediated by DNAX Accessory Molecule-1 Receptor", <i>The Journal of Immunology</i> , 161:1671-1676, (1998).	~[
	C29	Shibuya, K., et al., "Physical and Functional Association of LFA-1 with DNAM-1 Adhesion Molecule", Immunity, 11:615-623, (1999).	→
	C30	Suzuki, T., et al., 'Tax oncoprotein of HTLV-1 binds to the human homologue of Drosophila discs large tumor suppressor protein, hDLG, and perturbs its function in cell growth control", Oncogene, 18(44):5967-72, (1999).	0 0
	C31	Vallenius, T. et al. "CLP-36 PDZ-LIM Protein Associates with Nonmuscle alpha-Actinin-1 and alpha-Actinin-4." The Journal of Biological Chemistry, April 14, 2000; pp. 11100-11105, Vol. 275, No. 15.	VTER
	C32	Wechsler, A. et al. "Brain Spectrin binding to the NMDA receptor is regulated by phosphorylation, calcium and calmodulin." <i>The EMBO Journal</i> , 1998, pp. 3931-3939, Vol. 17, No. 14.	
	C33	Xia, H. et al. "Actinin-associated LIM Protein: Identification of a Domain Interaction between PDZ and Spectrin-like Repeat Motifs", <i>The Journal of Cell Biology</i> , October 1997, pp. 507-515, Vol. 139, No. 2.	
	C34	Yanagisawa, J., et al., "The Molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis", <i>J. Biol. Chem.</i> , 272(13):8539-8545, (1997).	
	C35	GenBank, Accession Number AF028823, 12/01/1999	
	C36 *	GenBank, Accession Number BM845132, 03/06/2002	
	C37 ¹	GenBank, Accession Number CB131761, 01/29/2003	
MB	C38 ¹	GenBank, Accession Number CB961389, 04/28/2003	
xaminer Signature		Date 3/22/04	\exists

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

EXAMINEX: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page of 5

Complete if Known				
Application Number	09/688,017			
Filing Date	October 13, 2000			
First Named Inventor	Lu, Peter S., et. al.			
Art Unit	1644			
Examiner Name	DeCloux, Amy M.			
Attorney Docket Number	020054-001110US			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
MB	C39 V	GenBank, Accession Number CB995033, 04/30/2003	
MB	C40	Genbank, Accession Number D86964, 02/07/1999	

RECEIVED

FEB 0 8 2004

TECH CENTER 1600/2900

	· · ·		
Examiner Signature	Date Considered	3/22/04	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation it not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the including section is the application from the translation for most of the USPTO. Time will vary depending upon the including section is a process of the application for most of the USPTO. Time will vary depending upon the including section is section to the user of the application for most of the USPTO. individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.